TICKERNERD
Menu
XENEXENEHealthcare · Biotechnology

XENE Stock Forecast: Xenon Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 2 Oct 2026
$38
−2.40% on the day

The 19 Wall Street analysts covering Xenon Pharmaceuticals, Inc. hold a median 12-month price target of $75 — +96.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 41 of 100 as at 3 Oct 2026 — in the lower half.

Market cap
$3.7B
Ticker Nerd rank
41 / 100
Median analyst target
$75
Analysts covering
19
Revenue$0.0
Operating income−$123.2M
Net income−$110.7M
Free cash flow−$95.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+2.9%
1M
−36.8%
YTD
−15.2%
1Y
−3.1%
From 52W high
−46.5%
From 52W low
+3.9%
$37
$71
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

XENE stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Xenon Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 3 Oct 2026
41 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
87
Revisions
64
Momentum
61
Value
59
Quality
48
Issuance
39
Accruals
36
Growth
27
Size
27

Volatility (87): The share price has been relatively steady.

Growth (27): Sales and profits are flat, shrinking, or growing more slowly than they were.

Size (27): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

XENE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on XENE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$40$60$80$100Jan 26Apr 26Jul 26Oct 26XENEHigh $97Median $75Low $46

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says19 analysts
18 Buy1 Hold0 Sell
Low $46Median $75High $97

The green dot is the last close — the median target sits +96.1% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 7 moved it down.

DateFirmActionRatingTarget
18 Sept 2026BairdMaintainsOutperform$97 → $90
18 Sept 2026Deutsche BankDowngradeHold$90 → $46
18 Sept 2026NeedhamMaintainsBuy$78 → $60
18 Sept 2026RBC CapitalMaintainsOutperform$81 → $70
18 Sept 2026WedbushMaintainsOutperform$71 → $55
18 Sept 2026Wells FargoMaintainsOverweight$69 → $64
7 Aug 2026RBC CapitalMaintainsOutperform$82 → $81
27 May 2026JP MorganMaintainsOverweight$80 → $82
27 May 2026JP MorganMaintainsOverweight—
12 May 2026JP MorganMaintainsOverweight—
8 May 2026NeedhamMaintainsBuy—
8 May 2026RBC CapitalMaintainsOutperform—
16 Mar 2026WedbushMaintainsOutperform—
10 Mar 2026Deutsche BankMaintainsBuy—
10 Mar 2026HC Wainwright & Co.MaintainsBuy—
10 Mar 2026WedbushMaintainsOutperform—
10 Mar 2026Wells FargoMaintainsOverweight—
9 Mar 2026BairdMaintainsOutperform—
9 Mar 2026NeedhamMaintainsBuy—
27 Feb 2026NeedhamMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. XENE appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

XENE vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 2 Oct 2026, Xenon Pharmaceuticals, Inc. returned −3.1% against +16.2% for the S&P 500, dividends included.

XENE vs S&P 500, last 12 monthsTotal return, rebased to 100
100120140160180Jan 26Apr 26Jul 26Oct 26XENES&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

XENE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
11
Analysts cutting
2
Fundamentals

Xenon Pharmaceuticals, Inc. (XENE) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−8.7×

Cheaper than 92% of US stocks

Price / sales
490.9×

Cheaper than 2% of US stocks

Price / book
3.0×

Cheaper than 32% of US stocks

EV / EBITDA
−6.3×

Cheaper than 81% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
−100.0%

Higher than 1% of US stocks

Gross margin
—
Operating margin
−4974.3%

Higher than 3% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−43.6%

Higher than 23% of US stocks

Return on assets
−28.0%

Higher than 15% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Xenon Pharmaceuticals, Inc. (XENE) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Xenon Pharmaceuticals, Inc. has a market value of $3.7B and an enterprise value of $2.8B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$409.2M.

  • Diluted earnings per share, trailing twelve months: $−4.74.

  • Free cash flow in the twelve months to 30 June 2026: −$338.5M.

  • Shares outstanding: 96.8M.

  • Trailing P/E: −8.7×; forward P/E: −8.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Xenon Pharmaceuticals, Inc. employs 358 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 5 Oct 2026

Data provided by Twelve Data

Peers

XENE vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
XENEXenon Pharmaceuticals, Inc.$3.7B
41
PBLSParabilis Medicines, Inc.$3.6B
0
CELCCelcuity, Inc.$3.5B
28
IDYAIDEAYA Biosciences, Inc.$3.5B
78
VKTXViking Therapeutics, Inc.$3.8B
32
TNGXTango Therapeutics, Inc.$3.8B
39
ACADACADIA Pharmaceuticals, Inc.$3.4B
77

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Xenon Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest XENE news & analysis

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 2 Oct 2026neutral

Xenon Pharmaceuticals announced equity inducement grants to eight new non-officer employees, consisting of 17,850 share options and 10,500 restricted share units. The grants were approved by the Compensation Committee with an effective date of October 1, 2026, and were issued under Nasdaq Listing Rule 5635(c)(4).

Why it matters — This signals the company is hiring new personnel, which XENE watchers may track as a routine corporate announcement related to employee retention and onboarding.

Defence Therapeutics Appoints Finance Executive Sherry Aulin to Its Board of Directors

Newsfile Corp · 29 Sept 2026neutral

Defence Therapeutics announced the appointment of finance executive Sherry Aulin to its Board of Directors, where she will also serve as a member of the company's Audit Committee. The announcement was made on September 29, 2026.

Why it matters — This news concerns Defence Therapeutics, a separate biotechnology company, and has no direct bearing on Xenon Pharmaceuticals' operations or outlook.

Xenon Files Azetukalner NDA as It Pauses Psychiatry Trials for Tolerability Review

MarketBeat · 27 Sept 2026neutral

Xenon Pharmaceuticals has filed its first new drug application for azetukalner as a treatment for focal-onset seizures. The company has also paused portions of its late-stage psychiatry program to evaluate changes intended to improve tolerability.

Why it matters — A XENE watcher would care because the NDA filing advances azetukalner's regulatory path while the psychiatry trial pause signals a potential shift in the drug's development timeline.

XENE Investors Have Opportunity to Join Xenon Pharmaceuticals Inc. Fraud Investigation with SBS Law

Business Wire · 23 Sept 2026negative

SBS Law announced that Xenon Pharmaceuticals Inc. (XENE) investors have an opportunity to join a fraud investigation into the company. The announcement was made via a Business Wire release from Los Angeles.

Why it matters — A fraud investigation could signal potential legal or regulatory exposure for Xenon Pharmaceuticals, which XENE watchers would want to monitor.

Xenon Pharmaceuticals Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Xenon Pharmaceuticals (XENE)

PRNewsWire · 22 Sept 2026negative

SueWallSt notified investors of a pending investigation into Xenon Pharmaceuticals following the company's disclosure of an enrollment pause in its Phase 3 depression trials for azetukalner. Analysts subsequently cut price targets and reduced estimates for the drug's psychiatric commercial opportunity, and XENE shares fell as much as 27.6%.

Why it matters — A XENE watcher would care because the enrollment pause in the Phase 3 depression trials, analyst estimate cuts, and the ensuing investigation could materially affect the company's outlook and share price.

FAQ

Frequently asked questions about XENE stock

What is the XENE stock price forecast for 2026-2027?

The 19 Wall Street analysts covering Xenon Pharmaceuticals, Inc. have a median 12-month price target of $75, with estimates ranging from $46 to $97. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is XENE stock a buy right now?

Of the 19 analysts covering Xenon Pharmaceuticals, Inc., 18 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Xenon Pharmaceuticals, Inc. 41 out of 100 across roughly 4,600 US stocks as at 3 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank XENE?

As at 3 Oct 2026, Xenon Pharmaceuticals, Inc. ranks 41 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (87 of 100).

Will XENE stock go up?

No one can know that. What the data says: the median 12-month target from 19 analysts implies +96.1% from the last close, and Ticker Nerd's factor model ranks Xenon Pharmaceuticals, Inc. 41 out of 100 as at 3 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the XENE stock forecast for 2030?

No analyst covering Xenon Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for XENE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $46 to $97 over the next 12 months.

How has XENE stock performed over the past year?

Xenon Pharmaceuticals, Inc. returned -3.1% over the 12 months to 2 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Xenon Pharmaceuticals, Inc. do?

Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company that develops therapies for neurological and psychiatric disorders.

What is the latest news on XENE?

The most recent item we track (GlobeNewsWire, 2 Oct 2026): "Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)". Xenon Pharmaceuticals announced equity inducement grants to eight new non-officer employees, consisting of 17,850 share options and 10,500 restricted share units. The grants were approved by the Compensation Committee with an effective date of October 1, 2026, and were issued under Nasdaq Listing Rule 5635(c)(4).

Company

About Xenon Pharmaceuticals, Inc.

Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company that develops therapies for neurological and psychiatric disorders. Xenon Pharmaceuticals Inc. concentrates on ion channel science and small-molecule drug discovery, with a pipeline centered on treatments for epilepsy and other central nervous system conditions. Its current programs include late-stage and early-stage candidates aimed at focal seizures, primary generalized tonic-clonic seizures, major depressive disorder, bipolar depression, and pain. The company operates as a single reportable segment focused on discovering, developing, and delivering therapeutics for patients with high unmet medical needs. Headquartered in Burnaby, British Columbia, Xenon Pharmaceuticals Inc. has an operating presence in North America and collaborates with clinical and research partners to advance its development programs.

CEO Mr. Ian C. Mortimer C.M.A., CPA, M.B.A. · 358 employees · Canada · https://www.xenon-pharma.com